Mereo BioPharma Group plc(MREO)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Mereo BioPharma Group plc (MREO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MREO at 9.4/100 on a 32-signal composite quality model, placing it at rank #2,916 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Mereo BioPharma Group plc reports net income of $-7.0M, free cash flow of $-6.0M. Top institutional holders of MREO by reported 13-F value include Rubric Capital Management, 683 Capital Management, BANK OF AMERICA, based on the most recent SEC filings. MREO trades on the Nasdaq exchange and files with the SEC under CIK 1719714. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MREO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Mereo BioPharma Group plc directly from SEC EDGAR.